

Publication List

2011

1. **Oshikawa G, Nagao T, Wu N, Kurosu T, Miura O:** c-Cbl and Cbl-b ligases mediate 17-allylaminodemethoxygeldanamycin-induced degradation of autophosphorylated Flt3 kinase with internal tandem duplication through the ubiquitin proteasome pathway. *J Biol Chem* 286:30263-30273, 2011.
2. **Nagao T, Oshikawa G, Wu N, Kurosu T, Miura O:** DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3beta. *PLoS ONE* 6:e27397, 2011.
3. **Arai A, Imadome K, Watanabe Y, Yoshimori M, Koyama T, Kawaguchi T, Nakaseko C, Fujiwara S, Miura O:** Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis. *Int J Hematol* 93:602-609, 2011.
4. **Imadome K, Yajima M, Arai A, Nakazawa A, Kawano F, Ichikawa S, Shimizu N, Yamamoto N, Morio T, Ohga S, Nakamura H, Ito M, Miura O, Komano J, Fujiwara S:** Novel mouse xenograft models reveal a critical role of CD4+ T cells in the proliferation of EBV-infected T and NK cells. *PLoS Pathog* 7:e1002326, 2011.
5. **Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, Nagai T, Ohnishi K, Maeda Y, Matsuda A, Amagasaki T, Yanada M:** Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. *Int J Hematol* 93:624-632, 2011.
6. **Ravella PM, Liu D, Kojima K, Weisberger J, Miura O, Kuyama J, Au W, Seiter K:** Acute promyelocytic leukemia with tetraploid karyotype: first report in the Western hemisphere and update of previous reports. *Leuk Res* 35:e93-95, 2011.
7. **Nakagawa Y, Suzuki K, Hirose T, Chou T, Fujisawa S, Kida M, Usuki K, Ishida Y, Taniguchi S, Kouzai Y, Tomoyasu S, Miyazaki K, Higashihara M, Ando K, Aoki S, Arai A, Akiyama N, Hatake K, Okamoto S, Dan K, Ohyashiki K, Urabe A:** Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study. *J Infect Chemother* 17:58-67, 2011.

2010

1. **Kurosu T, Wu N, Oshikawa G, Kagechika H, Miura O:** Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway. *Apoptosis* 15:608-620, 2010.
2. **Oshikawa G, Kurosu T, Arai A, Murakami N, Miura O:** Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation. *Cancer Genet Cytogenet* 199:56-61, 2010.
3. **Nakauchi Y, Takase H, Sugita S, Mochizuki M, Shibata S, Ishiwata Y, Shibuya Y, Yasuhara M, Miura O, Arai A:** Concurrent administration of intravenous systemic and

intravitreal methotrexate for intraocular lymphoma with central nervous system involvement. *Int J Hematol* 2010.

4. **Arai A, Imadome K, Fujiwara S, Miura O:** Autoimmune hemolytic anemia accompanied by reactivation of an Epstein-Barr virus infection with suppressed CTL response to EBV-infected cells in an elderly man. *Intern Med* 49:325-329, 2010.
5. **Kuninaka N, Kurata M, Yamamoto K, Suzuki S, Umeda S, Kirimura S, Arai A, Nakagawa Y, Suzuki K, Kitagawa M:** Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes is down-regulated during transformation to overt leukemia. *Exp Mol Pathol* 88:293-298, 2010.
6. **Okuhashi Y, Itoh M, Arai A, Nara N, Tohda S:** Gamma-secretase inhibitors induce erythroid differentiation in erythroid leukemia cell lines. *Anticancer Res* 30:4071-4074, 2010.

2009

1. **Kurosu T, Ohki M, Wu N, Kagechika H, Miura O:** Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. *Cancer Res* 69:3927-3936, 2009.
2. **Wakabayashi S, Arai A, Oshikawa G, Araki A, Watanabe M, Uchida N, Taniguchi S, Miura O:** Extranodal NK/T cell lymphoma, nasal type, of the small intestine diagnosed by double-balloon endoscopy. *Int J Hematol* 90:605-610, 2009.
3. **Nonaka M, Uota S, Saitoh Y, Takahashi M, Sugimoto H, Amet T, Arai A, Miura O, Yamamoto N, Yamaoka S:** Role for protein geranylgeranylation in adult T-cell leukemia cell survival. *Exp Cell Res* 315:141-150, 2009.
4. **Sugita S, Takase H, Sugamoto Y, Arai A, Miura O, Mochizuki M:** Diagnosis of intraocular lymphoma by polymerase chain reaction analysis and cytokine profiling of the vitreous fluid. *Jpn J Ophthalmol* 53:209-214, 2009.
5. **Hirokawa M, Sawada K, Fujishima N, Kawano F, Kimura A, Watanabe T, Arai A, Matsui T, Nakao S, Urabe A, Omine M, Ozawa K:** Acquired pure red cell aplasia associated with malignant lymphomas: a nationwide cohort study in Japan for the PRCA Collaborative Study Group. *Am J Hematol* 84:144-148, 2009

2008

1. **Kurosu T, Tsuji K, Ohki M, Miki T, Yamamoto M, Kakihana K, Koyama T, Taniguchi S, Miura O:** A variant-type MLL/SEPT9 fusion transcript in adult de novo acute monocytic leukemia (M5b) with t(11;17)(q23;q25). *Int J Hematol* 88:192-196, 2008.
2. **Kakihana K, Kubo F, Wakabayashi S, Kurosu T, Miki T, Murakami N, Miura O:** A novel variant form of MLL-ELL fusion transcript with t(11;19)(q23;p13.1) in chronic myelomonocytic leukemia transforming to acute myeloid leukemia. *Cancer Genet Cytogenet* 184:109-112, 2008.

3. **Morita-Hoshi Y, Tohda S, Miura O, Nara N:** An autopsy case of multicentric Castleman's disease associated with interstitial nephritis and secondary AA amyloidosis. *Int J Hematol* 87:69-74, 2008.
4. **Morita-Hoshi Y, Heike Y, Kawakami M, Sugita T, Miura O, Kim SW, Mori SI, Fukuda T, Tanosaki R, Tobinai K, Takaue Y:** Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation. *Bone Marrow Transplant* 41:515-521, 2008.
5. **Nemoto Y, Kanai T, Tohda S, Totsuka T, Okamoto R, Tsuchiya K, Nakamura T, Sakamoto N, Fukuda T, Miura O, Yagita H, Watanabe M:** Negative feedback regulation of colitogenic CD4+ T cells by increased granulopoiesis. *Inflamm Bowel Dis* 14:1491-1503, 2008.
6. **Tamai H, Yamaguchi H, Takahashi S, Tojo A, Hamaguchi H, Kobayashi T, Akiyama H, Sakamaki H, Okumura H, Nakao S, Arai A, Miura O, Tajika K, Inokuchi K, Dan K:** Treatment of adult AML with t(6;11)(q27;q23) by allogeneic hematopoietic SCT in the first CR. *Bone Marrow Transplant* 42:553-554, 2008.
7. **Tamai H, Yamaguchi H, Hamaguchi H, Yagasaki F, Bessho M, Kobayashi T, Akiyama H, Sakamaki H, Takahashi S, Tojo A, Ohmine K, Ozawa K, Okumura H, Nakao S, Arai A, Miura O, Toyota S, Gomi S, Murai Y, Usui N, Miyazawa K, Ohyashiki K, Takahashi N, Sawada K, Kato A, Oshimi K, Inokuchi K, Dan K:** Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study. *Int J Hematol* 87:195-202, 2008.
8. **Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, Teramura M, Karasawa M, Arai A, Yonemura Y, Nakao S, Urabe A, Omine M, Ozawa K:** Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. *Haematologica* 93:1555-1559, 2008.

2007

1. **Kida A, Kakihana K, Kotani S, Kurosu T, Miura O:** Glycogen synthase kinase-3beta and p38 phosphorylate cyclin D2 on Thr280 to trigger its ubiquitin/proteasome-dependent degradation in hematopoietic cells. *Oncogene* 26:6630-6640, 2007.
2. **Kurosu T, Tsuji K, Kida A, Koyama T, Yamamoto M, Miura O:** Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta. *Oncogene* 26:2975-2987, 2007.
3. **Yan W, Arai A, Aoki M, Ichijo H, Miura O:** ASK1 is activated by arsenic trioxide in leukemic cells through accumulation of reactive oxygen species and may play a negative role in induction of apoptosis. *Biochem Biophys Res Commun* 355:1038-1044, 2007.
4. **Teng Y, Takahashi Y, Yamada M, Kurosu T, Koyama T, Miura O, Miki T:** IRF4 negatively regulates proliferation of germinal center B cell-derived Burkitt's lymphoma cell lines and induces differentiation toward plasma cells. *Eur J Cell Biol* 86:581-589, 2007.

5. **Arai A, Yan W, Wakabayashi S, Hayashi S, Inazawa J, Miura O:** Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFR α -positive chronic eosinophilic leukemia followed by severe hepatotoxicity. *Int J Hematol* 86:233-237, 2007.
6. **Arai A, Kitano A, Sawabe E, Kanegane H, Miyawaki T, Miura O:** Relapsing *Campylobacter coli* bacteremia with reactive arthritis in a patient with X-linked agammaglobulinemia. *Intern Med* 46:605-609, 2007.
7. **Horibe S, Takagi M, Unno J, Nagasawa M, Morio T, Arai A, Miura O, Ohta M, Kitagawa M, Mizutani S:** DNA damage check points prevent leukemic transformation in myelodysplastic syndrome. *Leukemia* 21:2195-2198, 2007.

2006

1. **Jin A, Kurosu T, Tsuji K, Mizuchi D, Arai A, Fujita H, Hattori M, Minato N, Miura O:** BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion. *Oncogene* 25:4332-4340, 2006.
2. **Iiyama M, Kakihana K, Kurosu T, Miura O:** Reactive oxygen species generated by hematopoietic cytokines play roles in activation of receptor-mediated signaling and in cell cycle progression. *Cell Signal* 18:174-182, 2006.
3. **Arai A, Aoki M, Weihua Y, Jin A, Miura O:** CrkL plays a role in SDF-1-induced activation of the Raf-1/MEK/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells. *Cell Signal* 18:2162-2171, 2006.
4. **Arai A, Kitano A, Sawabe E, Kanegane H, Miyawaki T, Miura O:** Relapsing *Campylobacter coli* bacteremia with reactive arthritis in a patient with X-linked agammaglobulinemia. *Intern Med* 46:605-609, 2007.
5. **Koyama T, Nagao T, Tsunozaki H, Arai M, Miura O:** Successful management of massive intraperitoneal bleeding in a hemophilia A patient with inhibitor by surgical debridement of the incomplete hematoma and administration of recombinant factor VIII and activated factor VII. *Pathophysiol Haemost Thromb* 35:405-407, 2006.
6. **Morita Y, Heike Y, Kawakami M, Miura O, Nakatsuka S, Ebisawa M, Mori S, Tanosaki R, Fukuda T, Kim SW, Tobinai K, Takaue Y:** Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. *Int J Cancer* 119:1360-1367, 2006.

2005

1. **Jin ZH, Kurosu T, Yamaguchi M, Arai A, Miura O:** Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis. *Oncogene* 24:1973-1981, 2005.
2. **Kurosu T, Takahashi Y, Fukuda T, Koyama T, Miki T, Miura O:** p38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide. *Apoptosis* 10:1111-1120, 2005.

3. **Arai A, Jin A, Yan W, Mizuchi D, Yamamoto K, Nanki T, Miura O:** SDF-1 synergistically enhances IL-3-induced activation of the Raf-1/MEK/Erk signaling pathway through activation of Rac and its effector Pak kinases to promote hematopoiesis and chemotaxis. *Cell Signal* 17:497-506, 2005.
4. **Mizuchi D, Kurosu T, Kida A, Jin ZH, Jin A, Arai A, Miura O:** BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells. *Biochem Biophys Res Commun* 326:645-651, 2005.
5. **Kakihana K, Yamamoto M, Iiyama M, Miura O:** Calmodulin physically interacts with the erythropoietin receptor and enhances Jak2-mediated signaling. *Biochem Biophys Res Commun* 335:424-431, 2005.
6. **Arai A, Kitano A, Kurosu T, Yamamoto K, Miki T, Murakami N, Miura O:** Fluid retention during arsenic trioxide treatment in acute promyelocytic leukemia. *Am J Hematol* 79:247-248, 2005.
7. **Imadome K, Shimizu N, Arai A, Miura O, Watanabe K, Nakamura H, Nonoyama S, Yamamoto K, Fujiwara S:** Coexpression of CD40 and CD40 ligand in Epstein-Barr virus-infected T and NK cells and their role in cell survival. *J Infect Dis* 192:1340-1348, 2005.
8. **Morita Y, Hosokawa M, Ebisawa M, Sugita T, Miura O, Takaue Y, Heike Y:** Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation. *Bone Marrow Transplant* 36:803-811, 2005.

2004

1. **Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O:** The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. *Biochem Biophys Res Commun* 319:1272-1275, 2004.
2. **Morita Y, Takahashi A, Yamamoto K, Miki T, Murakami N, Miura O:** Secondary near-tetraploidy with double der(15)t(15;17) in acute promyelocytic leukemia in relapse. *Cancer Genet Cytogenet* 149:131-136, 2004.
3. **Haraguchi K, Takahashi T, Hiruma K, Kanda Y, Tanaka Y, Ogawa S, Chiba S, Miura O, Sakamaki H, Hirai H:** Recovery of Valpha24+ NKT cells after hematopoietic stem cell transplantation. *Bone Marrow Transplant* 34:595-602, 2004.
4. **Kaminuma O, Kitamura F, Kitamura N, Miyagishi M, Taira K, Yamamoto K, Miura O, Miyatake S:** GATA-3 suppresses IFN-gamma promoter activity independently of binding to cis-regulatory elements. *FEBS Lett* 570:63-68, 2004.

2003

1. **Kurosu T, Fukuda T, Miki T, Miura O:** BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells. *Oncogene* 22:4459-4468, 2003.

2. **Yamamoto K, Yamaguchi M, Miyasaka N, Miura O:** SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit. *Biochem Biophys Res Commun* 310:1188-1193, 2003.
3. **Kanda E, Jin ZH, Mizuchi D, Arai A, Miura O:** Activation of Rac and tyrosine phosphorylation of cytokine receptors induced by cross-linking of integrin alpha4beta1 and cell adhesion in hematopoietic cells. *Biochem Biophys Res Commun* 301:934-940, 2003.
4. **Yamaguchi M, Yamamoto K, Miura O:** Aberrant expression of the LHX4 LIM-homeobox gene caused by t(1;14)(q25;q32) in chronic myelogenous leukemia in biphenotypic blast crisis. *Genes Chromosomes Cancer* 38:269-273, 2003.
5. **Yamaguchi M, Yamamoto K, Miki T, Mizutani S, Miura O:** T-cell prolymphocytic leukemia with der(11)t(1;11)(q21;q23) and ATM deficiency. *Cancer Genet Cytogenet* 146:22-26, 2003.

2002

1. **Arai A, Kanda E, Miura O:** Rac is activated by erythropoietin or interleukin-3 and is involved in activation of the Erk signaling pathway. *Oncogene* 21:2641-2651, 2002.
2. **Yamamoto K, Shibata F, Miyasaka N, Miura O:** The human perforin gene is a direct target of STAT4 activated by IL-12 in NK cells. *Biochem Biophys Res Commun* 297:1245-1252, 2002.
3. **Sakashita C, Fukuda T, Okabe S, Kobayashi H, Hirose S, Tokuhisa T, Miyasaka N, Miura O, Miki T:** Cloning and characterization of the human BAZF gene, a homologue of the BCL6 oncogene. *Biochem Biophys Res Commun* 291:567-573, 2002.
4. **Yamamoto K, Shibata F, Yamaguchi M, Miura O:** Fusion of MLL and MSF in adult de novo acute myelomonocytic leukemia (M4) with t(11;17)(q23;q25). *Int J Hematol* 75:503-507, 2002.
5. **Zhang S, Fukushi M, Hashimoto S, Gao C, Huang L, Fukuyo Y, Nakajima T, Amagasa T, Enomoto S, Koike K, Miura O, Yamamoto N, Tsuchida N:** A new ERK2 binding protein, Naf1, attenuates the EGF/ERK2 nuclear signaling. *Biochem Biophys Res Commun* 297:17-23, 2002.
6. **Lekmine F, Sassano A, Uddin S, Majchrzak B, Miura O, Druker BJ, Fish EN, Imamoto A, Plataniias LC:** The CrkL adapter protein is required for type I interferon-dependent gene transcription and activation of the small G-protein Rap1. *Biochem Biophys Res Commun* 291:744-750, 2002.

2001

1. **Arai A, Nosaka Y, Kanda E, Yamamoto K, Miyasaka N, Miura O:** Rap1 is activated by erythropoietin or interleukin-3 and is involved in regulation of beta1 integrin-mediated hematopoietic cell adhesion. *J Biol Chem* 276:10453-10462, 2001.

2. **Arai A, Kanda E, Nosaka Y, Miyasaka N, Miura O:** CrkL is recruited through its SH2 domain to the erythropoietin receptor and plays a role in Lyn-mediated receptor signaling. *J Biol Chem* 276:33282-33290, 2001.
3. **Nosaka Y, Arai A, Kanda E, Akasaki T, Sumimoto H, Miyasaka N, Miura O:** Rac is activated by tumor necrosis factor alpha and is involved in activation of Erk. *Biochem Biophys Res Commun* 285:675-679, 2001.